title: Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16.
abstract: Moderately immunogenic HPV 16-associated tumours TC-1 (MHC class I(+), HPV 16 E6/E7(+), G12V Ha-ras(+)) and MK16/1/III ABC (MHC class I(-), HPV 16 E6/E7(+), G12V Ha-ras(+)), both of the H-2(b) haplotype and transplanted in syngeneic mice, were used to examine the adjuvant effects of IL-2 and dendritic cells for surgical therapy. Mice were inoculated s.c. with the respective tumour cells, and when the tumours reached 8-12 mm in diameter, they were extirpated. Three days after surgery, the experimental mice were treated with IL-2, IL-2 gene-modified tumour vaccines, or dendritic cells, injected s.c. to the site of previous surgery. It has been found in both, MHC class I(+) and MHC class I(-) tumours that the recombinant IL-2 and IL-2 gene-modified vaccines substantially reduced the tumour recurrence rate and inhibited growth of tumour recurrences. The dendritic cells were significantly effective only in mice with surgical minimal residual TC-1 (MHC class I(+)) tumour disease and when injected before they have reached the terminal stage of their differentiation.
authors.affiliation: Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Flemingovo nám 2, 166 37 6, Prague, Czech Republic. bubenik@img.cas.cz
authors.forename: Jan
authors.initials: J
authors.lastname: Bubeník
authors.forename: Romana
authors.initials: R
authors.lastname: Mikysková
authors.forename: Vladimír
authors.initials: V
authors.lastname: Vonka
authors.forename: Luis
authors.initials: L
authors.lastname: Mendoza
authors.forename: Jana
authors.initials: J
authors.lastname: Símová
authors.forename: Michal
authors.initials: M
authors.lastname: Smahel
authors.forename: Marie
authors.initials: M
authors.lastname: Indrová
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D019496:Cancer Vaccines / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003713:Dendritic Cells / Q000276:immunology*; D007376:Interleukin-2 / Q000008:administration & dosage*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D027383:Papillomaviridae; D030361:Papillomavirus Infections / Q000473:pathology / Q000601:surgery* / Q000628:therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage; D014407:Tumor Cells, Cultured; D014412:Tumor Virus Infections / Q000473:pathology / Q000601:surgery* / Q000628:therapy*
chemical_list: D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D007376:Interleukin-2; D011994:Recombinant Proteins